N
AARD

Nuveen’s Aardvark Therapeutics AARD Stock Holding History

Nuveen’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.7K Sell
15,312
-25,710
-63% -$267K ﹤0.01% 3202
2025
Q4 		$538K Buy
+41,022
New +$512K ﹤0.01% 2843

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen's AARD Position: Q1 2026 in Review

Nuveen reduced its Aardvark Therapeutics (AARD) stake by 63% in Q1 2026, selling an estimated $267K and leaving 15,312 shares worth $57.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3202.

Nuveen first reported a position in AARD in Q4 2025 and has held it in 2 quarters since. The position peaked at $538K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Nuveen held 15,312 shares of Aardvark Therapeutics worth $57.7K as of Q1 2026.
  • Nuveen sold 25,710 Aardvark Therapeutics shares in Q1 2026, an estimated $267K.
  • Aardvark Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3202 holding.
  • Nuveen first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Nuveen's Aardvark Therapeutics position peaked at $538K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.